[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632329":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":38,"centralContacts":42,"locations":48,"responsibleParty":67,"collaborators":29,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":29,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":29,"enrollmentInfo":78,"targetDuration":29,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":50,"whyStopped":29,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8,16,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Safety Lead-in Phase","EXPERIMENTAL","Participants will receive access to OpenEvidence CareConnect a Retrieval-Augmented Generation (RAG) Large Language Model (LLM) tool that provides general health and breast cancer-specific information for 3 months.",[13,14,15],"Other: Survey (Participant)","Other: OpenEvidence CareConnect","Other: Survey (Provider)",{"label":17,"type":10,"description":18,"interventionNames":19},"Interventional (Immediate Access)","Participants will be given immediate access to OpenEvidence CareConnect for up to 3 months and complete surveys regarding use of tool. Participants are then followed up for an additional 3 months.",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"Control (Delayed Access)","Participants will be given access to OpenEvidence CareConnect for 3 months 90 days after enrollment",[13,14,15],[25,30,34],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"Survey (Participant)","Participants will complete surveys to evaluate their experience using OpenEvidence CareConnect RAG LLM tool.",[21,17,9],null,{"type":6,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"OpenEvidence CareConnect","Retrieval-Augmented Generation (RAG) Large Language Model (LLM) tool",[21,17,9],{"type":6,"name":35,"description":36,"armGroupLabels":37,"otherNames":29},"Survey (Provider)","The provider will complete a survey to assess OpenEvidence CareConnect RAG LLM tool's usefulness and the quality of its patient education communication.",[21,17,9],[39],{"name":40,"affiliation":5,"role":41},"Michelle Melisko, MD","PRINCIPAL_INVESTIGATOR",[43],{"name":44,"role":45,"phone":46,"phoneExt":29,"email":47},"Ivy Ow","CONTACT","877-827-3222","Ivy.Wong@ucsf.edu",[49],{"facility":5,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"RECRUITING","San Francisco","California","94143","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-122.41942,37.77493,{"lat":60,"lon":59},[63,64,66],{"name":44,"role":45,"phone":46,"phoneExt":29,"email":47},{"name":29,"role":45,"phone":29,"phoneExt":29,"email":65},"cancertrials@ucsf.edu",{"name":40,"role":41,"phone":29,"phoneExt":29,"email":29},{"type":68,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100632329","generative-ai-patient-education-module-for-breast-oncology-100632329",false,"NCT07512271","Generative AI Patient Education Module for Breast Oncology","Accuracy and Effect of Prescribed Generative AI Patient Education Module Within Breast Oncology Care","Inclusion Criteria:\n\n1. Females or males ages 18 and over.\n2. Patients must have either:\n\n   1. Stage IV breast cancer facing a treatment change and are expected to have follow-up visits at least once every three months, or\n   2. Stage I-III breast cancer diagnosed within the past 6 months.\n3. Basic computer literacy and regular internet access at home.\n4. Able to understand study procedures and to comply with them for the entire length of the study.\n5. Ability of individual or legal guardian\u002Frepresentative to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n1. Contraindication to any study-related procedure or assessment.\n2. Cognitive impairment that would interfere with tool usage or survey completion","ALL","18 Years",{"count":79,"type":80},35,"ESTIMATED","INTERVENTIONAL",[83],"NA","This study evaluates the safety, accuracy, and impact of an artificial intelligence (AI) tool designed to support patient education in breast cancer care for breast oncology patients under selected physicians care within the University of California, San Francisco breast cancer center and affiliate sites.",[86,87,88],"Breast Cancer","Metastatic Breast Cancer","Carcinoma of the Breast",[90,91],"Artificial Intelligence (AI)","Digital Health","2026-08-04",{"date":94,"type":95},"2026-08-06","ACTUAL",{"date":97,"type":95},"2026-07-14",{"date":99,"type":80},"2027-01-31",{"name":5,"class":6},1]